TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE C

NCT07226648: Ultrasonic Neuromodulation of Cingulate Cortex for Fibromyalgia

Sponsor: SPIRE Therapeutics Inc. · Phase: PHASE2 · Area: CARDIOLOGY_METABOLIC · Target Enrollment: 180 pts

Competing Trials Overlap

7 Active Trials

Excess Burn Exposure

$1,328,000

Rescue Site Savings

+$863,200

Unlock Full NCT07226648 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT07226648 Rescue Dossier →